Mesa Laboratories MLAB Business Segments
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Biopharmaceutical Development | $48.63M-0.2% | $52.4M+8.5% | $50.26M+10.5% | $48.21M+12.6% | $48.73M+19.7% | |
| Clinical Genomics | $45.39M-3.6% | $44.72M-4.2% | $45.62M-2.1% | $45.97M-9.2% | $47.08M-10.5% | |
| Revenue by Product | ||||||
| Service | $45.74M+7.4% | $44.5M+5.8% | $43.69M+5.6% | $42.7M+5.2% | $42.58M+8.1% | |
| Revenue by Geography | ||||||
| CN | $20.45M-19.2% | $21.43M-19.5% | $22.11M-12.4% | $24.18M-4.7% | $25.31M+1.5% | |
| Other | $111.79M+12.9% | $108.07M+9.7% | $104.53M+9.5% | $100.77M+10.0% | $99.05M+16.7% | |
| US | $116.9M+0.2% | $118.04M+4.8% | $118.62M+10.1% | $117.4M+10.0% | $116.62M+9.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Mesa Laboratories break its business down?
- Mesa Laboratories (MLAB) reports revenue by business across 3 parts — Biopharmaceutical Development, Calibration Solutions and Clinical Genomics. Each is extracted from the segment footnotes and tracked over time.
- Where does Mesa Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Mesa Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
